| Psoriasis is a chronic,recurrent,non-infectious skin disease that is characterized by excessive proliferation and abnormal differentiation of epidermal keratinocytes for which there is no safe and effective treatment.A recent study found that Erianin has good biological activity against psoriasis.However,the poor water solubility and poor skin permeability of Erianin limit its clinical application.In order to improve the bioavailability and reduce the toxic side effects of Erianin,a light-responsive dendritic mesoporous silica drug-loaded controlled release system loaded with Erianin was constructed in this study,and its physicochemical properties were analyzed by a series of characterization techniques,and its slow and controlled release ability and therapeutic effects on psoriasis were investigated in vitro.The present study is divided into the following parts:(1)Three-dimensional dendritic mesoporous silicon nanoparticles(DMSN)were prepared and modified to obtain light-responsive dendritic mesoporous silicon nanoparticles(DMSN@FSP).The particle size,mesoporous parameters,dispersion and morphology of DMSN and DMSN@FSP were determined by dynamic light scattering,gas adsorption and desorption,and transmission electron microscopy.The structures of DMSN and DMSN@FSP were investigated by infrared spectroscopy,nuclear magnetic resonance and X-ray photoelectron spectroscopy.Further,the hydrophilicity and dispersibility of the nanoparticles were evaluated by analyzing the dispersity of the nanoparticles in water and PBS.The results show that the constructed DMSN@FSP has uniform particle size distribution,large specific surface area and pore capacity,good dispersibility and stability in water and PBS,and can be used as a delivery carrier for Erianin.(2)The optimal drug loading conditions were screened out,and the drug loading rate of Erianin was determined.The morphology,particle size,mesoporous parameters and dispersibility of the loaded nanoparticles were determined by dynamic light scattering,transmission electron microscopy,gas adsorption and desorption,etc.The surface groups of silicon(Eri-DMSN@FSP)were investigated.Subsequently,the presence state of Erianin in the nanoparticles was analyzed by differential scanning calorimetry and X-ray diffraction.Finally,the sustained-release and controlled-release effects of light-responsive dendritic mesoporous silicon nanoparticles loaded with Erianin were evaluated by in vitro release experiments.The results show that the light-responsive dendritic mesoporous silicon nanoparticles loaded with Erianin have uniform particle size and morphology distribution,good dispersibility,stable distribution of Erianin in mesoporous silicon,and have a significant slow-release and controlled-release effect.(3)The biocompatibility of Eri-DMSN@FSP,its anti-proliferative effect on psoriatic cells,and its sustained-release and controlled-release ability were studied by MTT experiments.The uptake ability of the drug loading system by psoriasis cells was evaluated by laser confocal microscopy,and its pro-apoptotic ability on psoriatic cells was studied by Annexin V-FITC double staining experiment.The results show that the Eri-DMSN@FSP constructed in this study has good biosafety,can load Erianin into psoriatic cells,and can release drugs in response to UV light of a specific wavelength,which has a good effect on psoriatic cells.activityinhibiting ability and pro-apoptotic effect. |
PDF Full Text Request